Celularity Stock
Celularity Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert Joseph Hariri
- Employees
- 115
- Market cap
- $41 M
- IPO
- 08/08/2019
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and…
Celularity stock: price history
1D
-6.0%
1W
-19.9%
1M
-3.1%
6M
+1.6%
YTD
+12.6%
1Y
-41.3%
2Y
-55.0%
5Y
-98.3%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~56% stronger price swings than usual
Ask the agents about Celularity
Analyst assessment of Celularity
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
3
BUY
2
HOLD
1
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 09/09/2025
Celularity stock metrics
P/E
-0.44
P/B
-1.03
EV/EBITDA
-1.66
RETURN ON EQUITY
-1.9%
NET MARGIN
17.6%
DEBT/EQUITY
-1.71
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
68.9%
FLOAT SHARES
22,372,816
AVG. DAILY VOLUME (30D)
149,545
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Celularity stock
What does Celularity do?
Celularity Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert Joseph Hariri, the company employs around 115 people.
The IPO was on 08/08/2019; the stock trades on NASDAQ under the ticker CELU.
What do analysts say about Celularity stock?
6 analysts rate the stock, the consensus is Buy (as of 09/09/2025).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Celularity report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 56% stronger than usual.
Does Celularity pay a dividend?
No, Celularity currently does not pay a dividend.
Which stocks are comparable to Celularity?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Celularity stock analyzed?
Clicking "Analyze stock" lets five strategies assess Celularity against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.